The recall was issued after routine testing identified the presence of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), a substance that has been deemed a potential carcinogen (cancer-causing substance) by the U.S. Food & Drug Administration (FDA).
Products affected by the recall include:
- Losartan Potassium tablets, USP 25 mg, are light-green, film-coated, teardrop-shaped biconvex tablet with “LK 25” on one side and “>” on the other side
- Losartan Potassium tablets, USP 100 mg, are dark green, film-coated, oval-shaped biconvex tablets with “LK100” on one side and “>” on the other side
The recalled Losartan was distributed exclusively to Camarillo, California-based Golden State Medical Supply, and sold in 30, 90 and 1,000 tablet quantities on the retail level.
Losartan Potassium is indicated for the treatment of hypertension, hypertensive patients with left ventricular hypertrophy, and nephropathy in Type 2 diabetic patients.
If you have been prescribed Losartan that is affected by this recall, you should not stop taking it without consulting your physician first, as doing so could result in adverse physical consequences.
To date, no reports of cancer or other adverse events have been linked to the recalled Losartan.
Source: FOX 8 Cleveland